Clinical reference Biomarker Directory
Back to directory

OGA

Emerging

OGA regulates a protein modification relevant to tau pathology; OGA inhibitors are an early-stage neurodegenerative disease drug approach.

Also known as O-GlcNAcase MGEA5
In plain language

This enzyme removes a specific chemical tag from proteins, including tau (a protein central to Alzheimer's disease). Drugs that block this enzyme are being tested as a way to potentially protect against harmful tau buildup, though this approach is still experimental.

Biomarker & context

O-GlcNAcase (OGA) is an enzyme that removes a specific sugar modification (O-GlcNAc) from proteins, involved in regulating cellular signaling pathways and implicated in tau protein biology.

What it indicates

OGA activity affects the balance of O-GlcNAc modification on tau protein, which is thought to influence pathological tau aggregation relevant to Alzheimer's disease and other tauopathies, connecting to the MAPT/tau discussion elsewhere in this biomarker set.

Diagnosis & clinical testing

OGA is primarily assessed in research settings (enzyme activity assays, brain imaging in clinical trials) rather than via a standard clinical blood test.

Guiding treatment

OGA inhibitor drugs are in early clinical development as a potential approach to reduce pathological tau aggregation in neurodegenerative disease by increasing protective O-GlcNAc modification on tau, though this remains investigational rather than clinical practice.

Clinical significance

Remains investigational; not yet a standard clinical biomarker or approved therapeutic target.

References
  1. General neurology/biochemistry reference literature on OGA and O-GlcNAc modification in tau pathology research.